AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17262200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 116
Study 17262200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular involvement
Number of subjects: 116
Study 16508637 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (CPT‐11 150 mg m(‐2) on d1, L‐OHP 65 mg m(‐2) on d2, LV 200 mg m(‐2) on days 2 and 3, 5‐FU 400 mg m(‐2) as i.v. bolus and 600 mg m(‐2) as 22 h i.v. continuous infusion on days 2 and 3, every 2 weeks)
Number of subjects: 283
Study 16508637 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (CPT‐11 180 mg m(‐2) on d1, LV and 5‐FU administered as in FOLFOXIRI, every 2 weeks)
Number of subjects: 283
Study 12773077 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 0
Study 12773077 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 0
Study 12773077 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 0
Study 11095480 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC patients (18 women)
Number of subjects: 18
Study 11095480 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 women)
Number of subjects: 18
Study 11095480 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry of 178 CNC patients
Number of subjects: 18
Study 11095480 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC patients (12 who died of other causes)
Number of subjects: 18
Study 9001874 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving with an inner coloured pair of gloves
Number of subjects: 100
Study 9001874 — intervention group
Group type: COMPARATOR
Intervention: Double gloving with classic gloves
Number of subjects: 100
Study 1473453 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2%
Number of subjects: 75
Study 1473453 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2% with FAT-MLV
Number of subjects: 75
Study 1473453 — intervention group
Group type: COMPARATOR
Intervention: Control group (FAT-MLV)
Number of subjects: 75
Study 6364396 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength cow's milk (FCM)
Number of subjects: 74
Study 6364396 — intervention group
Group type: COMPARATOR
Intervention: Graduated milk
Number of subjects: 74
Study 31231838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg/day
Number of subjects: 143
Study 31231838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not diagnosed with ED)
Number of subjects: 143
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not taking antihypertensive medication with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants <65 years of age with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants =65 years of age with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Whites with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 28634217 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese-Americans with SBP/DBP <140/90 mm Hg
Number of subjects: 31856
Study 26210342 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus supplemental education intervention
Number of subjects: 711
Study 26210342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 711
Study 23937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) using typical student norms
Number of subjects: 1663
Study 23937346 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Personalized Normative Feedback (PNF) using specific reference groups
Number of subjects: 1663
Study 23937346 — intervention group
Group type: COMPARATOR
Intervention: Repeated-assessment control
Number of subjects: 1663
Study 23937346 — intervention group
Group type: COMPARATOR
Intervention: Web-BASICS intervention
Number of subjects: 1663
Study 21350366 — intervention group
Group type: COMPARATOR
Intervention: Engerix B, 20 μg HBsAg
Number of subjects: 336
Study 21350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix B, 40 μg
Number of subjects: 336
Study 21350366 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix, 20 μg HBsAg combined with 720 ELU hepatitis A antigen
Number of subjects: 336
Study 18637980 — intervention group
Group type: COMPARATOR
Intervention: Women without hypertension
Number of subjects: 7149
Study 18637980 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hypertension
Number of subjects: 7149
Study 17306408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation interventions based on the SOFMER methodology
Number of subjects: 0
Study 17306408 — intervention group
Group type: COMPARATOR
Intervention: Comparative controlled studies including randomized controlled trials, controlled clinical trials, cohort studies, case control studies, reviews of clinical trials, and case series
Number of subjects: 0
Study 15569067 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood stored for 1, 2, 6, or 18 hours before filtration
Number of subjects: 48
Study 11360130 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-targeted nutrition counselling
Number of subjects: 140
Study 9765723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus supportive care
Number of subjects: 1190
Study 9765723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens containing cisplatin
Number of subjects: 1190
Study 9765723 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (not specified)
Number of subjects: 1190
Study 9765723 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy using long-term alkylating agents other than cisplatin
Number of subjects: 1190
Study 9765723 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (general)
Number of subjects: 1190
Study 9765723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 1190
Study 8119822 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration using a leukocyte filter incorporated in the bypass circuit (n = 8)
Number of subjects: 15
Study 8119822 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study 3691624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 200 mg
Number of subjects: 6
Study 3691624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 400 mg
Number of subjects: 6
Study 3691624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 600 mg
Number of subjects: 6
Study 3691624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 200 mg, 400 mg, 600 mg
Number of subjects: 6
Study 29273892 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 49
Study 29273892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 49
Study 27033753 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT
Number of subjects: 96
Study 27033753 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR
Number of subjects: 96
Study 27033753 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT + DNR
Number of subjects: 96
Study 25623162 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised intervention in addition to usual care
Number of subjects: 285
Study 25623162 — intervention group
Group type: COMPARATOR
Intervention: Attention and activity control in addition to usual care
Number of subjects: 285
Study 25623162 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 285
Study 23664208 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 20
Study 23664208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ranibizumab and PDT
Number of subjects: 20
Study 23664208 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery (Control)
Number of subjects: 20
Study 21920206 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous electrical nerve stimulation) for one hour
Number of subjects: 30
Study 21920206 — intervention group
Group type: COMPARATOR
Intervention: Control group (G2) without TENS (electrodes placed but equipment not turned on)
Number of subjects: 30
Study 18158000 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and Support Program (TSP); 8 weekly sessions, 1 hour each, taught by qualified therapists.
Number of subjects: 188
Study 18158000 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list); offered TSP after 4 months.
Number of subjects: 188
Study 16259645 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d nemifitide
Number of subjects: 81
Study 16259645 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg/d nemifitide
Number of subjects: 81
Study 16259645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 12611031 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (SST) for 8 weeks
Number of subjects: 120
Study 12611031 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 120
Study 10674778 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus immune globulin intravenous (RSV‐IGIV)
Number of subjects: 0
Study 10674778 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 10674778 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV‐IGIV or palivizumab
Number of subjects: 0
Study 8831163 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginary trauma writing
Number of subjects: 0
Study 8831163 — intervention group
Group type: EXPERIMENTAL
Intervention: Real trauma writing
Number of subjects: 0
Study 8831163 — intervention group
Group type: COMPARATOR
Intervention: Both trauma groups (Imaginary and Real)
Number of subjects: 0
Study 8831163 — intervention group
Group type: COMPARATOR
Intervention: Control group (trivial events)
Number of subjects: 0
Study 1280735 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 34826 (400 mg every 6 hours for five doses)
Number of subjects: 6
Study 3966709 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 3966709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31334680 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted suprapubic salpingectomy (LASS)
Number of subjects: 57
Study 31334680 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 57
Study 30366815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with polyethylene glycol)
Number of subjects: 261
Study 30366815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Number of subjects: 261
Study 27132170 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Number of subjects: 24
Study 27132170 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a
Number of subjects: 24
Study 27132170 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrcludex B + PegIFNα‐2a
Number of subjects: 24
Study 26016365 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation training (including meditation, unarmed run, yoga, and stepping in hot lab environment)
Number of subjects: 40
Study 26016365 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation training
Number of subjects: 40
Study 26016365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study 23259260 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplegia-triple-needling method combined with conventional rehabilitation training
Number of subjects: 48
Study 23259260 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture therapy combined with conventional rehabilitation training
Number of subjects: 48
Study 21082868 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg daily for 18 months
Number of subjects: 1623
Study 21082868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1623
Study 17573687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian perspective in clinical trials
Number of subjects: 0
Study 17573687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian philosophy
Number of subjects: 0
Study 17573687 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for Bayesians
Number of subjects: 0
Study 16190570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-based retherapy
Number of subjects: 0
Study 16190570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Number of subjects: 0
Study 16190570 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with pegylated interferon
Number of subjects: 0
Study 16190570 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of consensus interferon and ribavirin
Number of subjects: 0
Study 12521969 — intervention group
Group type: EXPERIMENTAL
Intervention: Single education session for nursing staff and provision of three hip protectors per resident
Number of subjects: 942
Study 12521969 — intervention group
Group type: COMPARATOR
Intervention: Usual care with brief information to nursing staff and provision of two hip protectors per cluster
Number of subjects: 942
Study 11431944 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg tranexamic acid before skin incision and after the start of cardiopulmonary bypass
Number of subjects: 14
Study 11431944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 14
Study 11431944 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg tranexamic acid
Number of subjects: 14
Study 9191679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed femoral nailing
Number of subjects: 39
Study 9191679 — intervention group
Group type: COMPARATOR
Intervention: Reamed femoral nailing
Number of subjects: 39
Study 1447560 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal reading speed (first paragraph)
Number of subjects: 45
Study 1447560 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled text condition (second paragraph)
Number of subjects: 45
Study 1447560 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized spaces condition (third paragraph)
Number of subjects: 45
Study 1447560 — intervention group
Group type: COMPARATOR
Intervention: Control (normal paragraph)
Number of subjects: 45
Study 3722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term indwelling catheters
Number of subjects: 16
Study 3722838 — intervention group
Group type: COMPARATOR
Intervention: Bed-pads
Number of subjects: 16
Study 28673805 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl Alcohol (PVA) gelatin tubes
Number of subjects: 0
Study 28673805 — intervention group
Group type: COMPARATOR
Intervention: Silicone tubes
Number of subjects: 0
Study 27334236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) for 16 weeks (8 weeks LED + 8 weeks normal food intake with 2 LED products/day) followed by 48 weeks of weight maintenance diet
Number of subjects: 60
Study 24756913 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine duplex ultrasonography
Number of subjects: 94
Study 24756913 — intervention group
Group type: COMPARATOR
Intervention: Selective duplex ultrasonography
Number of subjects: 94
Study 22840421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin (L+Z) 10 mg/2 mg; n = 1044
Number of subjects: 4203
Study 22840421 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 long‐chain polyunsaturated fatty acids (LCPUFA) (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069)
Number of subjects: 4203
Study 22840421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L+Z and ω‐3 LCPUFAs; n = 1078
Number of subjects: 4203
Study 22840421 — intervention group
Group type: EXPERIMENTAL
Intervention: Original AREDS formulation with variations in zinc and β‐carotene
Number of subjects: 4203
Study 22840421 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n = 1012
Number of subjects: 4203
Study 20723301 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus dipyridamole (100 mg/day)
Number of subjects: 32
Study 20723301 — intervention group
Group type: COMPARATOR
Intervention: Simple chemotherapy
Number of subjects: 32
Study 20723301 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy individuals)
Number of subjects: 32
Study 18305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 10
Study 18305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 10
Study 18305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 10
Study 18305947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15877873 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated mineral water (1 litre daily for 8 weeks)
Number of subjects: 18
Study 15877873 — intervention group
Group type: COMPARATOR
Intervention: Control mineral water (1 litre daily for 8 weeks)
Number of subjects: 18
Study 12823129 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-specific IgE detected in asthmatic children
Number of subjects: 155
Study 12823129 — intervention group
Group type: COMPARATOR
Intervention: Nonallergic children
Number of subjects: 155
Study 11961334 — intervention group
Group type: EXPERIMENTAL
Intervention: Original blackcurrant drink
Number of subjects: 12
Study 11961334 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental blackcurrant drink
Number of subjects: 12
Study 11961334 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 12
Study 11961334 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 10546009 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrinologists
Number of subjects: 260
Study 10546009 — intervention group
Group type: COMPARATOR
Intervention: Generalists
Number of subjects: 260
Study 8649278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 20 mg/kg/12h
Number of subjects: 66
Study 8649278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 8 mg/kg/8h
Number of subjects: 66
Study 8649278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 13 mg/kg/8h
Number of subjects: 66
Study 8649278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal Quinimax 20 mg/kg/8h
Number of subjects: 66
Study 8649278 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular quinine 8 mg/kg/8h
Number of subjects: 66
Study 8649278 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine 12.5 mg/kg in a slow infusion over 4 hours/12h
Number of subjects: 66
Study 8649278 — intervention group
Group type: EXPERIMENTAL
Intervention: New rectal quinine formulation 12.8 mg/kg/8h quinine gluconate
Number of subjects: 66
Study 2260567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 189
Study 2260567 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 189
Study 7426887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over ten seconds
Number of subjects: 0
Study 7426887 — intervention group
Group type: COMPARATOR
Intervention: Slow injection of meglumine ioxitalamate (380 mg I/ml, 1.5 ml/kg bodyweight) over two minutes
Number of subjects: 0
Study 6151828 — intervention group
Group type: EXPERIMENTAL
Intervention: Butofilolol (200 mg, administered 24 hours and 2 hours before the test)
Number of subjects: 20
Study 6151828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double blind)
Number of subjects: 20
Study 30231943 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-all strategy (decolonization bundle for all patients without S. aureus screening)
Number of subjects: 0
Study 30231943 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat strategy (decolonization bundle if S. aureus found, otherwise SOC)
Number of subjects: 0
Study 30231943 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC - 2 disinfectant soap showers)
Number of subjects: 0
Study 27465250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:400,000
Number of subjects: 25
Study 27465250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:200,000
Number of subjects: 25
Study 27465250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:100,000
Number of subjects: 25
Study 27465250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine concentration of 1:50,000
Number of subjects: 25
Study 24488610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of Cyclosporin-A (2.5 mg/kg)
Number of subjects: 78
Study 24488610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 24488610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (CsA) in higher-risk patients
Number of subjects: 78
Study 23477118 — intervention group
Group type: EXPERIMENTAL
Intervention: No nasal packing
Number of subjects: 66
Study 23477118 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 66
Study 19890345 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with inhaled nitric oxide (20 p.p.m. of iNO)
Number of subjects: 56
Study 19890345 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation with FiO2 1.0 (Control group)
Number of subjects: 56